Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The ubiquitin-proteasome system is a major pathway for protein degradation, so that proteasome is now considered as an important target for drug discovery. Bortezomib, the first US FDA-approved proteasome inhibitor now used as a front-line treatment for multiple myeloma. To better understand the effects of bortezomib in cancer treatment, we carried out a review based on 32 published clinical trials to determine whether bortezomib will benefit patients with solid tumors. Information of complete response, partial response, stable disease and objective response rate was collected to assess clinical outcomes. A lack of therapeutic effects was observed when bortezomib was used as a single agent. Meanwhile, when bortezomib treatment was combined with other agents, bortezomib offered no statistically significant response versus these agents alone. High-quality studies are required to better understand the clinically effects of bortezomib and the development of a new generation of proteasome inhibitors is absolutely necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Ubiquitin signalling in the NF-κB pathway
Chen, Z. J. (2005) · Nature Cell Biology · doi:10.1038/ncb0805-758 · Cited by 1,184
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
Clinical development of novel proteasome inhibitors for cancer treatment
Yang, H., Zonder, J. A., & Dou, Q. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903002074 · Cited by 85
Hainsworth, J. D., Meluch, A. A., Spigel, D. R., Barton, J., Simons, L., Meng, C., Gould, B., & Greco, F. A. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.004 · Cited by 49
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239
Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA–mRNA Interaction Involvement
Łuczkowska, K., Rogińska, D., Ulańczyk, Z., Paczkowska, E., Schmidt, C. A., & Machaliński, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010350 · Cited by 26
Metadata
- Authors
- Huang, Z., Wu, Y., Zhou, X., Xu, J., Zhu, W., Shu, Y., & Liu, P.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2014-08-31
- Volume
- 10
- Issue
- 10
- Pages
- 1795-1807
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2004252053
- Cited by
- 127
- References
- 6
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials. https://app.cochat.ai/papers/10.2217/fon.14.30
- The paper
- Huang, Z., Wu, Y., Zhou, X., Xu, J., Zhu, W., Shu, Y., & Liu, P. (2014). Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials. Future Oncology. https://doi.org/10.2217/fon.14.30
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.